Paper Details 
Original Abstract of the Article :
The safety of regadenoson (Reg) during low-level exercise testing has been established. However, its administration at peak exercise for patients who do not reach target heart rate (THR) on standard exercise treadmill stress testing (ETT) needs to be established, particularly among patients with kno...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1007/s00259-012-2296-4

データ提供:米国国立医学図書館(NLM)

Regadenoson: A Safe and Tolerable Stress Agent for SPECT MPI

Stress myocardial perfusion imaging (SPECT MPI) is a valuable diagnostic tool for assessing coronary artery disease. Regadenoson, a vasodilator, is often used to induce stress during SPECT MPI. This study investigates the safety and tolerability of regadenoson administration at peak exercise in patients who did not reach target heart rate (THR) on standard exercise treadmill stress testing (ETT). The authors examined hemodynamics, side effects, and adverse events in a cohort of 514 patients undergoing SPECT MPI, with and without known coronary artery disease.

Regadenoson: A Safe and Effective Stress Agent at Peak Exercise

The study found that regadenoson was safe and well-tolerated when administered at peak exercise in patients who did not reach THR on ETT. The authors observed no significant differences in side effects or adverse events between patients with and without coronary artery disease. These findings provide reassurance regarding the safety of regadenoson administration at peak exercise, expanding its potential use in SPECT MPI.

Expanding the Applications of Regadenoson in SPECT MPI

This study provides valuable information for clinicians performing SPECT MPI. The authors' findings demonstrate the safety and tolerability of regadenoson administration at peak exercise, even in patients with known coronary artery disease. This expands the potential use of regadenoson as a stress agent in SPECT MPI, enabling clinicians to obtain accurate diagnostic information for a broader range of patients.

Dr.Camel's Conclusion

This study provides a reassuring oasis in the desert of cardiac imaging. The authors demonstrate the safety and tolerability of regadenoson, a vital tool in SPECT MPI, even in patients with coronary artery disease. This finding helps us to navigate the complex landscape of cardiac diagnostics with greater confidence, ensuring accurate diagnoses and improved patient care.

Date :
  1. Date Completed 2013-08-01
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23208701

DOI: Digital Object Identifier

10.1007/s00259-012-2296-4

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.